A 24-Week Randomized Double-blind Placebo-Controlled Study Evaluating Efficacy And Safety Of Adalimumab (D2E7)Plus Methotrexate (MTX) In Patients With Active Rheumatoid Arthritis (RA) Despite Treatment With Methotrexate.

Trial Profile

A 24-Week Randomized Double-blind Placebo-Controlled Study Evaluating Efficacy And Safety Of Adalimumab (D2E7)Plus Methotrexate (MTX) In Patients With Active Rheumatoid Arthritis (RA) Despite Treatment With Methotrexate.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms ARMADA
  • Most Recent Events

    • 01 Jan 2003 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top